AR101721A1 - ANTIBODIES AND RECEPTORS OF CHEMICAL ANTIGENS SPECIFIC TO CD19 - Google Patents
ANTIBODIES AND RECEPTORS OF CHEMICAL ANTIGENS SPECIFIC TO CD19Info
- Publication number
- AR101721A1 AR101721A1 ARP150102778A ARP150102778A AR101721A1 AR 101721 A1 AR101721 A1 AR 101721A1 AR P150102778 A ARP150102778 A AR P150102778A AR P150102778 A ARP150102778 A AR P150102778A AR 101721 A1 AR101721 A1 AR 101721A1
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- receptors
- binding
- disease
- antigens specific
- Prior art date
Links
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Moléculas de unión a CD19, que incluyen anticuerpos anti-CD19, que incluyen fragmentos de anticuerpo tales como fragmentos de cadena simple y receptores quiméricos que incluyen los anticuerpos, tales como los receptores de antígenos quiméricos (CARs). Entre los anticuerpos hay anticuerpos humanos, que incluyen los que compiten por la unión a CD19 con anticuerpos de referencia, como anticuerpos murinos. En algunas formas de realización, los anticuerpos presentan propiedades funcionales similares a los anticuerpos de referencia, tales como afinidades de unión comparables y/o propiedades de inhibición competitiva. También se proveen células genéticamente modificadas que expresan los receptores quiméricos y usos de las moléculas de unión y las células en las terapias celulares adoptivas. Reivindicación 49: Un método de tratamiento, caracterizado porque comprende administrar el anticuerpo de cualquiera de las reivindicaciones 1 a 33 a un sujeto que tiene una enfermedad o trastorno asociado con CD19. Reivindicación 50: El método de cualquiera de las reivindicaciones 47 a 49, caracterizado porque la enfermedad o trastorno es una malignidad de células B.CD19 binding molecules, which include anti-CD19 antibodies, which include antibody fragments such as single chain fragments and chimeric receptors that include antibodies, such as chimeric antigen receptors (CARs). Among the antibodies are human antibodies, which include those that compete for binding to CD19 with reference antibodies, such as murine antibodies. In some embodiments, the antibodies have similar functional properties to the reference antibodies, such as comparable binding affinities and / or competitive inhibition properties. Genetically modified cells expressing the chimeric receptors and uses of binding molecules and cells in adoptive cell therapies are also provided. Claim 49: A method of treatment, characterized in that it comprises administering the antibody of any of claims 1 to 33 to a subject having a disease or disorder associated with CD19. Claim 50: The method of any of claims 47 to 49, characterized in that the disease or disorder is a B-cell malignancy.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462043273P | 2014-08-28 | 2014-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101721A1 true AR101721A1 (en) | 2017-01-11 |
Family
ID=58698671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102778A AR101721A1 (en) | 2014-08-28 | 2015-08-28 | ANTIBODIES AND RECEPTORS OF CHEMICAL ANTIGENS SPECIFIC TO CD19 |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR101721A1 (en) |
-
2015
- 2015-08-28 AR ARP150102778A patent/AR101721A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20170023A7 (en) | ANTIBODIES AND RECEIVERS OF CHEMICAL ANTIGENS SPECIFIC TO CD19 | |
| MX2021009151A (en) | Antibodies and chimeric antigen receptors specific for ror1. | |
| CL2020001151A1 (en) | Chimeric antigen receptors specific for the b-cell maturation antigen and polynucleotides encoding the same. | |
| MX2020004243A (en) | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen. | |
| SV2018005634A (en) | ANTI-BCMA ANTIBODIES, BIO-SPECIFIC ANTIGEN MOLECULES THAT JOIN BCMA AND CD3, AND USES OF THESE | |
| CO2017010495A2 (en) | Antibodies that bind bcma and / or cd3 | |
| DOP2018000212A (en) | MOLECULES OF UNION TO BCMA AND METHODS OF USE OF THE SAME | |
| CL2019000146A1 (en) | Anti-gprc5d antibodies, biospecific antigen binding molecules that bind gprc5d and cd3, and related uses. | |
| CO2020008972A2 (en) | Lipid Nanoparticle Containing Nucleic Acid and Use of It | |
| BR112019011450A2 (en) | modified natural killer cells and their use | |
| CO2017010502A2 (en) | Chimeric antigen receptors targeting the b-cell maturation antigen | |
| CR20190095A (en) | T cell receptors and immune therapy using the same | |
| EA201791093A1 (en) | ANTIBODIES TO CD47, METHODS AND USE | |
| AR066198A1 (en) | ANTI IGE APOPTOTIC ANTIBODIES | |
| EA201791554A1 (en) | BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20 | |
| MX2020007021A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor. | |
| EA201592269A1 (en) | METHODS AND COMPOSITIONS FOR REDUCING IMMUNOSUPRESSION BY TUMOR CELLS | |
| PE20181054A1 (en) | HUMANIZED ANTI-CD19 ANTIBODIES AND METHODS OF USE | |
| AR083293A1 (en) | UNION AGENTS TO CD33 | |
| GT201200318A (en) | ANTIBODIES TO GDF8 HUMAN | |
| EA201400625A1 (en) | ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION | |
| EA201591791A1 (en) | MAN PAC1 ANTIBODIES | |
| EA201400447A1 (en) | ANTIBODIES TO CD1d | |
| MX2020004910A (en) | Compositions and methods for the depletion of cd5+ cells. | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells |